Kytopen

Kytopen is focused on the development and commercialization of groundbreaking genome engineering platforms for expediting the discovery, development, and manufacture of gene-modified cell therapies. Developed at MIT, the Flowfect platform, harmonizing microfluidics and automation, revolutionizes the delivery of genome engineering materials to cells of therapeutic interest in an expeditious, scalable, and economically advantageous manner compared to current alternatives. In May 2023, Kytopen unveiled the Flowfect DiscoverTM, an automated high-throughput genome engineering platform, and disclosed strategic partnerships with industry-leading Contract Development and Manufacturing Organizations (CDMOs) and translational academic medical centers. By combining Flowfect DiscoverTM with the Flowfect TxTM large-scale delivery device...

Transfection,immunotherapy,cell engineering,mechanical engineering,genetic engineering,mammalian cells,manufacturing,immunology,crispr,car t-cell,drug discovery,cell therapy,gene therapy,stem cells,gene editing,mrna,rnp delivery,nk cells,cd34+ stem cells,t cells,cas9,and nonviral

Kytopen operates in the Biotechnology research industry.

Kytopen's revenue is 11m - 100m

Kytopen has 11 - 50 employees.